ProCE Banner Activity

Pharmacists’ FAQs on the Use of PARP Inhibitors for Ovarian Cancer

Clinical Thought
Read this commentary from Colleen Bohnenkamp, PharmD, BCOP, BCPS, and Dane Fritzsche, PharmD, BCOP, on frequently asked questions regarding pharmacists’ use of PARP inhibitors for ovarian cancer.

Released: December 07, 2021

Expiration: December 06, 2022

Share

Faculty

Colleen Bohnenkamp

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Dane Fritzsche

Dane Fritzsche, PharmD, BCOP

Clinical Instructor
Department of Pharmacy
University of Washington
Clinical Oncology Pharmacist
Pharmacy
Seattle Cancer Care Alliance/UW Medicine
Seattle, WA

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie Inc.

GlaxoSmithKline

Partners

CSPE

ProCE Banner

National Association of Specialty Pharmacy

ProCE Banner

Faculty Disclosure

Primary Author

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Colleen Bohnenkamp, PharmD, BCOP, BCPS, has disclosed that she has no conflicts of interest to report.

Dane Fritzsche, PharmD, BCOP

Clinical Instructor
Department of Pharmacy
University of Washington
Clinical Oncology Pharmacist
Pharmacy
Seattle Cancer Care Alliance/UW Medicine
Seattle, WA

Dane Fritzsche, PharmD, BCOP, has disclosed that he has no conflicts of interest to report.